Showing results (21-30 of 610) with videos related to
Sort By:
Pageof 61
Molecular Cancer Therapeutics|April 22, 2014
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitorsRodrigo Dienstmann, Jordi Rodon, Violeta Serra, et al.Molecular Oncology|December 23, 2011
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancerRodrigo Dienstmann, Sara De Dosso, Enriqueta Felip, et al.Nature Reviews. Cancer|January 5, 2017
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancerRodrigo Dienstmann, Louis Vermeulen, Justin Guinney, et al.Molecular Oncology|January 31, 2019
New clinical trial designs in the era of precision medicineElena Garralda, Rodrigo Dienstmann, Alejandro Piris-Giménez, et al.Cancer Chemotherapy and Pharmacology|March 28, 2015
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3Morten Mau-Sørensen, Christian Dittrich, Rodrigo Dienstmann, et al.Nature Reviews. Clinical Oncology|April 5, 2012
Molecular prescreening to select patient population in early clinical trialsJordi Rodón, Cristina Saura, Rodrigo Dienstmann, et al.Cellular Oncology (Dordrecht, Netherlands)|January 15, 2015
Intrinsic cancer subtypes--next steps into personalized medicineCristina Santos, Rebeca Sanz-Pamplona, Ernest Nadal, et al.Current Treatment Options in Oncology|November 6, 2021
The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal CancerJavier Ros, Iosune Baraibar, Giulia Martini, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2017
Tumor Side as Model of Integrative Molecular Classification of Colorectal CancerRodrigo DienstmannMolecular Cancer Research : MCR|March 22, 2007
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agentsJosep TaberneroPageof 61